Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Arun Azad, Andrew J. Armstrong, Antonio Alcaraz, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey M. Holzbeierlein, Arnauld Villers, B. Yа. Alekseev, Taro Iguchi, Neal D. Shore, F. Gómez-Veiga, Brad Rosbrook, Ho‐Jin Lee, Gabriel P. Haas, Arnulf Stenzl
Topics & Concepts
EnzalutamideMedicineProstate cancerDocetaxelInternal medicineClinical endpointOncologyAndrogen deprivation therapyPlaceboPopulationHazard ratioProstate-specific antigenClinical trialCancerConfidence intervalPathologyAlternative medicineEnvironmental healthAndrogen receptorProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsCancer, Lipids, and Metabolism